AstraZeneca and Eli Lilly are to continue with a pivotal phase 2/3 study of a key pipeline drug, AZD3293 for early Alzheimer's disease, after interim safety data boosted confidence in the d
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.